alexa HLA-Genotype in Multiple Sclerosis: The Role in Disease onset, Clinical Course, Cognitive Status and Response to Treatment: A Clear Step Towards Personalized Therapeutics | Abstract

Immunogenetics: Open Access
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

HLA-Genotype in Multiple Sclerosis: The Role in Disease onset, Clinical Course, Cognitive Status and Response to Treatment: A Clear Step Towards Personalized Therapeutics

Petros Stamatelos1 and Maria Anagnostouli1,2*

1Immunogenetics Laboratory, 1st Department of Neurology, Medical School of National and Kapodistrian University of Athens, Aeginition Hospital, Athens, Greece

2Demyelinating Diseases Clinic, 1st Department of Neurology, Medical School of National and Kapodistrian University of Athens, Aeginition Hospital, Athens, Greece

*Corresponding Author:
Maria C Anagnostouli
Assistant Professor in Neurology, Director of Immunogenetics Laboratory
1st Department of Neurology, Medical School of National and Kapodistrian
University of Athens, Aeginition Hospital, Athens, Greece
Tel: +30 6944 431973
E-mail: [email protected]

Received date: April 07, 2017; Accepted date: May 06, 2017; Published date: May 11, 2017

Citation: Stamatelos P, Anagnostouli M (2017) HLA-Genotype in Multiple Sclerosis: The Role in Disease onset, Clinical Course, Cognitive Status and Response to Treatment: A Clear Step Towards Personalized Therapeutics. Immunogenet open access 2:116.

Copyright: © 2017 Stamatelos P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Multiple Sclerosis (MS) is probably the best studied chronic inflammatory and demyelinating disease of the Central Nervous System (CNS), with a clear impact on patients’ quality of life. Many factors have been described to play a role in the initiation and clinical course of the disease, as well as in the response to medication. These factors include age at onset, gender, viral infections, Human Leucocyte Antigen (HLA)-genotype, non-HLA genes, Vitamin D levels and smoking. HLA genetic profile is the most important one, as it not only influences every aspect of the disease, but it also modifies the effect of the other factors.

In this review article we summarize the decisive effect of HLA-genotype on MS initiation, clinical course, cognitive impairment and therapeutically outcome, as well as on other demyelinating diseases of the CNS (including Neuromyelitis Optica and Acute Disseminated Encephalomyelitis). HLA-DRB1*15:01 is the best established allele, both increasing the risk of MS 2-3 times and influencing response to first line medication (including Interferon-beta and Glatiramer Acetate), but neutralizing antibodies’ formation against natalizumab, as well. Other Class I and Class II HLA alleles have either a detrimental (DRB1*08:01, 03:01, 13:03, 15:03, 04:05) or a protective (DRB1*14:01, *07, *11, A*02:01) effect on MS. Taking into account their epistatic interactions, we conclude that HLA-genotyping may lead to an individualized approach of MS patients, in different ethnic groups.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7